Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584140 · ClinicalTrials.gov registry record · Phase 4
Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT02584140: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT02584140 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 136 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02584140, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to test a program that uses drug level monitoring, text messaging ("iTAB") and personalized counseling with HIV prevention services, including PrEP (medicine that can help prevent HIV infection when taken daily).
Primary Outcome
Adherence is measured by TFV-DP (tenofovir diphosphate) concentrations in Dried Blood Spots (DBS) suggestive of 6-7 doses per week.
Interventions
- BEHAVIORAL Text Messaging
- BEHAVIORAL Adherence Counseling
- DRUG Daily Oral PrEP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 4 |
What the finished NCT02584140 record still lists
NCT02584140 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which Text Messaging is the first listed.
NCT02584140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02584140 about?
NCT02584140 is a clinical study titled "Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women". The purpose of this study is to test a program that uses drug level monitoring, text messaging ("iTAB") and personalized counseling with HIV prevention services, including PrEP (medicine that can help prevent HIV infection when taken daily).
What is the current status of trial NCT02584140?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2016-05. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT02584140?
The interventions under investigation include: Text Messaging (BEHAVIORAL), Adherence Counseling (BEHAVIORAL), Daily Oral PrEP (DRUG).
Who is sponsoring clinical trial NCT02584140?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02584140's enrollment target sits among peer trials
136 596th of 2000 higher than 1,400 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia